The conjunctival transcriptome in Ethiopians after trichiasis surgery: associations with the development of eyelid contour abnormalities and the effect of oral doxycycline treatment by Derrick, Tamsyn et al.
RESEARCH ARTICLE
The conjunctival transcriptome in Ethiopians after trichiasis 
surgery: associations with the development of eyelid contour 
abnormalities and the effect of oral doxycycline treatment 
[version 1; peer review: 1 approved, 1 approved with 
reservations]
Tamsyn Derrick 1,2, Esmael Habtamu 1,3, Zerihun Tadesse3, E. Kelly Callahan4, 
Abebaw Worku5, Bizuayehu Gashaw5, David Macleod 1, David C.W. Mabey1, 
Martin J. Holland 1, Matthew J. Burton 1
1London School of Hygiene and Tropical Medicine, London, UK 
2Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
3The Carter Center, Addis Ababa, Ethiopia 
4The Carter Center, Atlanta, USA 
5Amhara Regional Health Bureau, Bahirdar, Ethiopia 
First published: 04 Sep 2019, 4:130  
https://doi.org/10.12688/wellcomeopenres.15419.1





Background: Surgery to correct trichiasis is a key component of the 
World Health Organisation trachoma control strategy, however 
unfavourable outcomes such as eyelid contour abnormalities (ECA) 
following surgery are relatively common. This study aimed to 
understand the transcriptional changes associated with the early 
development of ECA and the impact of doxycycline, which has anti-
inflammatory and anti-fibrotic properties, upon these transcription 
patterns. 
Methods: One thousand Ethiopians undergoing trichiasis surgery 
were enrolled in a randomised controlled trial following informed 
consent. Equal groups of randomly assigned individuals were orally 
administered with 100mg/day of doxycycline (n=499) or placebo 
(n=501) for 28 days. Conjunctival swabs were collected immediately 
prior to surgery and at one- and six-months post-surgery. 3’ mRNA 
sequencing was performed on paired baseline and one-month 
samples from 48 individuals; 12 in each treatment/ECA outcome 
group. qPCR validation was then performed for 46 genes of interest in 
145 individuals who developed ECA at one month and 145 matched 
controls, using samples from baseline, one and six months. 
Results: All treatment/outcome groups upregulated genes associated 
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with wound healing pathways at one month relative to baseline, 
however no individual differences were detected between groups. The 
summed expression of a highly coexpressed cluster of pro-fibrotic 
genes was higher in patients that developed ECA in the placebo group 
relative to controls. qPCR validation revealed that all genes in this 
cluster and a number of other pro-inflammatory genes were strongly 
associated with ECA, however these associations were not modulated 
by trial arm. 
Conclusions: The development of post-operative ECA is associated 
with overexpression of pro-inflammatory and pro-fibrotic genes 
including growth factors, matrix metalloproteinases, collagens and 
extracellular matrix proteins. There was no evidence that doxycycline 
modulated the association between gene expression and ECA.
Keywords 
Trichiasis, conjunctiva, eyelid contour abnormalities, post-operative, 
scarring, inflammation, doxycycline
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Introduction
Trachoma is a neglected tropical disease and the world’s lead-
ing infectious cause of blindness. Disease is initiated during 
childhood by repeated infection of the conjunctival epithelium 
with the intracellular bacterium Chlamydia trachomatis. This 
can lead to recurrent episodes of pathological inflammation 
which persist throughout the lives of some individuals and are 
a major risk factor for the development of scarring1. Scarring of 
the tarsal conjunctiva causes the lid margin and eyelashes 
to turn inwards, known as entropion and trichiasis, respec-
tively, such that the lashes brush against the cornea causing 
mechanical damage, pain and ultimately blindness. In 2017 
over 200,000 people worldwide were managed for trichi-
asis; the disease is found predominantly in sub-Saharan Africa2. 
Trachomatous inflammation and scarring can progress in the 
absence of detectable chlamydial infection1,3, therefore it is 
expected that trichiasis surveillance and management provisions 
will be required for many years in formerly endemic districts.
Trachoma is controlled at the population level through imple-
mentation of the SAFE Strategy: Surgery to correct trichi-
asis, Antibiotics for infection control, and Facial cleanliness 
and Environmental improvements to prevent infection trans-
mission. However, recurrence rates following trichiasis surgery 
range between 12–22% within 12 months and unfavourable 
outcomes such as the development of eyelid contour abnor-
malities (ECA) following surgery are relatively common, 
occurring in around 10% of patients4,5.
ECA involves notching or distortion of the eyelid margin. 
When ECA is severe the eyelid may no longer cover the globe 
of the eye when closed (lagophthalmos), increasing the risk 
of corneal damage and vision loss6. Unfavourable aesthetic 
outcomes such as ECA may also dissuade patient’s friends 
or relatives from undergoing trichiasis surgery and may be 
stigmatising7–9. The pathophysiology of ECA is unknown, 
although it is likely due to an aberrant post-operative wound 
healing response involving excessive fibrosis and contraction 
of the tarsal conjunctiva. Previous studies have shown that a 
number of innate epithelial pro-inflammatory mediators (IL1B, 
S100A7, CXCL5), matrix factors (SPARCL1, CTGF, collagens) 
and matrix metalloproteinases (MMPs 7, 9, 12) are associated 
with progressive trachomatous scarring, trichiasis and recurrence 
post-surgery1,10,11. MMPs are thought to facilitate fibro-
sis through remodelling the extracellular matrix (ECM) and 
enabling inflammatory cell infiltration. Failure of glaucoma fil-
tration surgery is associated with excessive ECM deposition 
and contraction of subconjunctival tissue12, and a number of 
collagen genes were found to be upregulated in the conjunc-
tivae of patients with fibrotic outcomes following glaucoma 
surgery13. These pro-inflammatory and matrix factors may 
also have a role in the development of ECA.
Doxycycline is a tetracycline-based antibiotic that is used 
clinically to treat sexually transmitted C. trachomatis infec-
tion. Several reports have presented evidence that doxycycline 
reduces inflammatory gene expression14–17 and it inhibits 
MMPs by reducing their expression, blocking their activation 
and inhibiting protease activity through directly binding zinc 
and calcium ions in the catalytic site18. Doxycycline is used 
clinically to reduce inflammation and prevent fibrosis in 
diseases including rosacea, idiopathic pulmonary fibrosis and 
corneal erosion19–21. Li and colleagues presented data showing 
that doxycycline inhibited matrix remodelling and contrac-
tion and reduced MMP expression in primary fibroblasts 
isolated from individuals undergoing trichiasis surgery22. These 
data therefore suggest that doxycycline could have a protective 
effect against the development of recurrent trichiasis and ECA. 
In order to address this question a randomised, double-blind, 
placebo-controlled trial was conducted to determine the 
impact of doxycycline treatment on post-operative trichiasis. 
One thousand Ethiopians eligible for trichiasis surgery were 
enrolled in the trial and the findings have been published in full 
elsewhere5. Surprisingly, the cumulative proportion of indi-
viduals who developed recurrent trichiasis by 12 months after 
surgery was the same in both groups; 58/498 (12%) in the 
doxycycline group and 62/501 (12%) in the placebo group. 
There was also no difference in the proportion of individuals 
with mild, moderate or severe ECA at one, six or twelve months.
This study sought to understand the transcriptional changes 
associated with the early development of ECA following 
trichiasis surgery and the impact of doxycycline upon these 
transcription patterns. It was nested within the overall clinical 
trial and took place in parallel.
Methods
Ethics
This study was approved by the ethics committee of the Lon-
don School of Hygiene & Tropical Medicine, Emory Uni-
versity Institutional Review Board, the Ethiopian National 
Health Research Ethics Review Committee and the Ethiopia 
Food, Medicine and Healthcare Administration and Controls 
Authority. The study was conducted in accordance with the 
Declaration of Helsinki and the International Conference on 
Harmonisation–Good Clinical Practice guidelines. Written 
informed consent or a witnessed thumbprint was requested 
from all study participants following detailed explanation of 
the study in Amharic.
Surgery and examination
One thousand Ethiopians eligible for trichiasis surgery were 
enrolled in a randomised, double blind, placebo-controlled 
trial (registered with the Pan African Clinical Trials Registry, 
trial number PACTR201512001370307, registration date 29th 
November 2015, registration URL: https://pactr.samrc.ac.za/
TrialDisplay.aspx?TrialID=1370). Eligible individuals had evi-
dence of trichiasis (one or more lashes touching the eye or 
evidence of epilation) and trachomatous scarring of the tar-
sal conjunctiva, were aged ≥ 18 years and had not had previous 
trichiasis surgery. Trichiasis surgery was performed using the 
posterior lamellar tarsal rotation (PLTR) procedure by expe-
rienced nurse-surgeons who had recently undergone refresher 
training. All study participants received 1% tetracycline eye 
ointment for self-administration twice a day for two weeks 
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post-surgery. Participants were randomly assigned (1:1) to 
receive either 100mg/day doxycycline or 100mg/day placebo, 
orally administered, for 28 consecutive days after surgery.
Study participants were examined at baseline (immediately 
prior to surgery), 10 days, one month, six months and twelve 
months post-surgery. Examinations were performed by two 
standardised examiners with very strong agreement on primary 
outcome (k=0.92) (at baseline and twelve months (EH) and 
at one and 6 months), using 2.5X loupes and a torch. Clinical 
signs of trachoma (follicles, papillae and cicatrice; FPC) were 
graded using the detailed WHO grading system23. Clinical signs 
or evidence of trichiasis, epilation and corneal scarring were 
recorded as previously described5. At baseline, scarring was 
graded using the detailed FPC grading system, whereas after 
surgery scarring was graded using the post-operative scarring 
grading system24. Sutures were removed on day 10. The pri-
mary outcome of the overall trial was the cumulative propor-
tion of individuals who developed post-operative trichiasis by 
12 months. Post-operative trichiasis was defined as minor (1–5 
eyelashes touching the eye or evidence of epilation in less than 
a third of the eyelid margin) or major (≥6 eyelashes touching 
the eye or evidence of epilation in a third or more of the 
eyelid margin). ECA at one, six or 12 months was included 
as a secondary trial outcome. ECA was graded as previously 
described4,6: mild (vertical deviation from the natural contour 
less than 1 mm in height and affecting more than one third of 
horizontal eyelid length); moderate (vertical deviation from the 
natural contour 1–2 mm in height or affecting one third to two 
thirds of horizontal eyelid length) and severe (vertical devia-
tion from the natural contour more than 2 mm in height or a 
defect more than two thirds the horizontal eyelid length). Mild 
ECA is considered clinically non-significant whereas mod-
erate and severe ECA are considered clinically significant. 
Drug adherence was monitored through interviews and by 
counting the number of capsules remaining. Full trial details and 
results are published elsewhere5.
Sample collection
Swabs from the tarsal conjunctiva were collected at base-
line and at one, six- and twelve-months post-surgery. A sterile 
polyester swab (Puritan) was passed across the conjunctival 
surface four times, with a quarter-turn on each pass. Swabs 
were stored in RNAlater (Thermo Fisher Scientific) at 4°C 
overnight and then long-term at -80°C. Swabs were shipped 
(on dry ice) to Kilimanjaro Christian Medical Centre (KCMC), 
Tanzania for processing. RNA and DNA were extracted from 
swabs using Norgen RNA/DNA purification kit (Norgen 
Biotek) following manufacturer’s instructions.
Chlamydia trachomatis testing
DNA samples were tested for C. trachomatis using a pub-
lished qPCR assay25. Samples were tested in duplicate using the 
triplex assay which detects a human endogenous control gene 
(RPP30), C. trachomatis plasmid (pORF2) and chromosomal 
(omcB) targets. Each reaction of 20μl contained 10μl TaqMan 
Multiplex Master Mix (Thermo Fisher Scientific), 300nM of 
each primer and probe (Thermo Fisher Scientific), 4μl water 
and 4μl sample DNA. Samples were tested on a ViiA7 ther-
mal cycler (Thermo Fisher Scientific) with the following con-
ditions: a 20 second hold at 95°C, followed by 40 cycles of 
95°C for one second and 60°C for 20 seconds. Samples were 
determined C. trachomatis positive if RPP30 and both chlamy-
dial targets (pORF2 and omcB) were positive in either or 
both replicates. Target concentration was calculated by 
extrapolating from a standard curve.
3’RNA sequencing
3’RNA sequencing was performed on paired baseline and one-
month samples from 48 individuals; 12 in each treatment/ 
outcome group (Placebo-Good outcome, Placebo-Poor out-
come, Doxycycline-Good outcome, Doxycycline-Poor outcome). 
All 48 individuals had moderate trachomatous scarring and no 
eyelid distortion at baseline (Detailed FPC scarring grade 2). 
Individuals with Poor outcomes had scarring distortion 
(SC4 or SC5) at one and six months, grade 2 or 3 ECA at 
one month, and grade 1, 2 or 3 ECA at six months. Indi-
viduals with Good outcomes had no scarring distortion or 
ECA at one and six months. Potential participants were selected 
at random (randomisation was performed in STATA v15) 
from each of the four treatment/outcome groups.
Library preparation was performed using QuantSeq 3’ mRNA-
Seq Library Prep Kit FWD for Illumina (Lexogen GmbH, 
Austria), following the manufacturer’s instructions. 3’ RNA 
sequencing generates one read per transcript at the 3’ end of 
polyadenylated mRNA and maintains strand-specificity. Sample 
RNA concentration was measured using Qubit HS RNA kits 
(Thermo Fisher Scientific) and RNA quality was tested using 
Agilent RNA 6000 Pico chips (Agilent Technologies, USA). 
Sample concentrations were normalised to 10ng/μl and 5μl 
RNA was used for library preparation. The PCR Add-on kit 
(Lexogen GmbH) was used during sample preparation to 
generate libraries that were not under or over-cycled. Final 
library concentration was tested using Agilent DNA chips and 
libraries were normalised to 6nM prior to pooling. Libraries were 
shipped to Lexogen GmbH for quality control and sequencing on 
two lanes of an Illumina HiSeq (Illumina).
Bam files were converted to FastQ using Picard and FastQ 
files were uploaded to BlueBee Genomics Platform (Blue-
Bee). FastQ files were trimmed and quality filtered using the 
default Integrated QuantSeq FWD workflow. In brief, Bbduk 
was used to trim low-quality tails, adapter contamination and 
polyA read-through, reads were aligned to human genome ver-
sion GRCh38.77 using STAR Aligner and reads were counted 
using HTSeq-count with kit-specific options. Raw and processed 
RNAseq data are deposited within the NCBI GEO public database 
(accession number GSE135455).
Gene expression
Of the 1000 participants in the clinical trial, a total of 145 
had developed moderate or severe ECA (grade 2 or 3) at the 
one-month time-point5. These 145 individuals and 145 age, 
sex and trial arm matched individuals without ECA (none 
or mild ECA (grade 0 or 1)) at one month were selected for 
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qPCR validation of gene expression, using samples from baseline, 
one month and six months; making a total of 870 samples.
RNA was converted to cDNA using SuperScript VILO 
cDNA synthesis kits (Thermo Fisher Scientific) following 
the manufacturer’s instructions. The relative abundance of 46 
genes of interest and endogenous control genes HPRT1 and 
GAPDH were quantified in each sample by qPCR using 
TaqMan Microfluidic 384-well Array Cards (Thermo Fisher 
Scientific). qPCR was performed using TaqMan Universal 
Master Mix (Thermo Fisher Scientific) on a ViiA7 thermal 
cycler following the manufacturer’s instructions. Genes of interest 
were selected based on 3’RNA sequencing results, those 
hypothesised to be involved in the pathogenesis of scar-
ring trachoma and genes reported to be immunomodulated by 
doxycycline1,10,14–17,22,26,27.
After running the first 239 samples and noting poor amplifica-
tion or failure of a number of samples on TaqMan Array Cards, 
all remaining samples were tested for HPRT1 expression by sin-
gle-plex qPCR for quality screening. qPCR was performed using 
a HPRT1 TaqMan Assay (the same as that used on the Array 
Card (assay ID: Hs02800695_m1; Thermo Fisher Scientific) 
and TaqMan Universal Master Mix on a ViiA7 thermal cycler 
following the manufacturer’s instructions. A cycle threshold 
value of 31 was determined as the screening cut-off based on 
data from Array Cards that had already been run. Of the 631 
remaining samples that had not yet been run on Array Cards, 
63 had HPRT1 qPCR CT values >31. After excluding failed 
samples and those that did not pass HPRT1 screening, 772/870 
samples remained with gene expression data.
Data analysis
3’RNA sequencing analysis. Read count data were down-
loaded from BlueBee and imported to R (www.R-project.org, 
R version 3.5.1) for analysis. Read count data were analysed 
for differential expression using DEseq2, adjusting for sex and 
age28. Genes were retained in the analysis that had a read count 
of 10 or more in 48 or more samples (n=11424). The DEseq2 
package internally corrects for library size and a plot of the 
Cook’s distance between samples revealed no sample out-
liers (data not shown) therefore no samples were excluded 
from the analyses. Samples were assigned to four groups; 
doxycycline and good outcome, doxycycline and ECA, placebo 
and good outcome, placebo and ECA. The differences in gene 
expression at one month relative to baseline in paired samples 
from each group was compared initially. The differences in gene 
expression between baseline and one month within each group 
were then contrasted between groups in pairwise comparisons. 
P values were adjusted by the Benjamini and Hochberg 
method within the DEseq2 package. Principal component 
analysis was performed within DEseq2 using read count data. 
The matrix of raw read counts for all 96 samples and 11424 
genes was entered into Miru v1.0 (https://kajeka.com; now 
called Graphia) to investigate clusters of samples with highly 
correlated expression values. The Pearson correlation cutoff 
was increased to the maximum possible whilst still retaining all 
96 samples (cutoff = 0.93).
Genes with an adjusted P value (Padj) <0.1 and FC>1.5 within 
each group at one month relative to baseline were entered into 
Gene Set Over-representation analysis in Consensus Path Data-
base (CPDB, http://consensuspathdb.org), using all 11424 
genes as background, minimum overlap with input list=2 and 
P value cutoff=0.01.
The matrix of raw read counts for all 96 samples and 11424 
genes was transposed and entered again into Miru to investi-
gate networks of co-expressed genes. Genes were clustered 
by Pearson correlation coefficient using a cutoff >=0.88. The 
genes in each cluster were also entered into Gene Set Over-rep-
resentation analysis in CPDB using 11424 genes as background. 
For each individual, the read counts for all genes in each 
cluster were summed, creating a single summative value per 
cluster. These summative values were then contrasted between 
one-month post-surgery treatment/outcome groups using 
linear regression, using the placebo/good outcome group as 
the reference group and adjusting for baseline (pre-surgery) 
expression, age and sex.
qPCR. Gene expression results were imported into STATA v15 
for analysis. Cycle threshold values in each sample were nor-
malised to the endogenous control gene (HPRT1) to gener-
ate delta CT values29. For quality control purposes, both genes 
and observations (a sample from a participant at one time-point) 
with 10% missing data were excluded. This resulted in the 
exclusion of two genes, PAPPA and TRGV9, and 22/772 obser-
vations, leaving 46 genes (44 genes of interest in addition to 
HPRT1 and GAPDH) and 751 observations in the analysis.
A binary ECA variable was created for analysis purposes 
based on the clinical significance criteria at each of the one- 
and six-month time-points: none or mild ECA (grades 0 or 1) 
= 0 and moderate and severe ECA (grades 2 or 3) = 1. In order 
to determine whether any of the shortlisted genes were associ-
ated with ECA, mixed effects logistic regression models were 
constructed with binary ECA as the dependant variable and 
the delta CT values of each gene in turn as the independent 
variable, adjusting for trial arm, age and sex, and using data 
from baseline, one and six months. Participant identifica-
tion number was included as a random effect to account for 
samples from the same individuals being used from multi-
ple timepoints. C. trachomatis was not adjusted for in these 
analyses due to the very low number of infections detected. 
Following these initial models, the models were performed 
again including an interaction term between gene expres-
sion and treatment arm, to determine whether treatment arm 
modified the effect of gene expression on ECA outcome. A like-
lihood ratio test was then performed to determine whether the 
model including the interaction explained the data better than 
the model without the interaction. The Benjamini and Hochberg 
method was used to control for a false discovery rate of 5%30.
Results
RNA sequencing
3’RNA sequencing was performed on samples from 48 
individuals at baseline (immediately prior to surgery) and at 
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one-month post-surgery, making a total of 96 samples. All 
48 individuals had moderate trachomatous scarring and no 
eyelid distortion at baseline (FPC scarring grade 2). Of these 
48 individuals, there were 12 in each treatment/outcome group: 
Placebo-Good outcome, Placebo-Poor outcome, Doxycycline- 
Good outcome, Doxycycline-Poor outcome. The demographic 
and clinical characteristics of these 48 individuals are shown in 
Table 1.
After filtering out genes that had a read count <10 in 48 or 
more samples, 11,424 genes were retained. RNA sequencing 
analysis revealed that within each of the four groups (Placebo-
Good; Placebo-Poor; Doxycycline-Good; Doxycycline-Poor), 
a large number of genes were differentially regulated at one 
month relative to baseline (Table 2). In each group, roughly 
twice as many genes were upregulated as were downregulated. 
More genes were differentially regulated in the Poor groups 
relative to the Good groups in both placebo and doxycy-
cline treatment arms. Whilst the number of differentially 
expressed genes was similar in both Poor groups, there were 
a higher number of differentially expressed genes in the 
doxycycline-Good group relative to the placebo-Good group.
Differentially expressed genes (Padj<0.1, FC>1.5) within 
each treatment/outcome group at one month relative to base-
line were entered into pathway analysis. The ten most enriched 
pathways for each group are shown in Table 3. All pathways 
were reflective of wound healing responses, including ECM 
organisation, collagen formation and interactions between cells 
and the ECM. The two Poor outcome groups were enriched 
for several immune response pathways that were not present 
in the top ten enriched pathways of the Good outcome groups 
(Table 3).
The differences in gene expression at one month relative to 
baseline within each treatment/outcome group were then con-
trasted between groups. Pairwise comparisons revealed almost 
no significant differences in gene expression between groups 
(Table 4). Four genes (PSD3, ZEB1, RAD17, RNF181) 
were differentially expressed in the placebo group, and one 
Table 1. Clinical and demographic details of 48 participants included in the RNAsequencing 
study.
Placebo-Good Placebo-Poor Doxycycline-Good Doxycycline-Poor
Total 12 12 12 12
Age (mean, range) 40.3 (20-60) 56.5 (35-80) 50.7 (30-75) 56.8 (41-75)
Sex (female/12) 9 10 8 8
C. trachomatis detected 0 0 0 0
ECA at 1 month: none 12 0 12 0
ECA at 1 month: 2 0 8 0 11
ECA at 1 month: 3 0 4 0 1
Scarring at 1 month: SC3 12 0 12 0
Scarring at 1 month: SC4 0 10 0 11
Scarring at 1 month: SC5 0 2 0 1
Table 2. The number of differentially expressed genes within each 



















a Upregulated genes had higher expression at 1 month relative to baseline
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(NUAK2) in the doxycycline group, between Good and Poor 
outcomes (Padj<0.1, FC>1.5). There were no overall differ-
ences between placebo and doxycycline groups (irrespective of 
outcome). Four genes were differentially expressed between 
Good and Poor outcomes (irrespective of treatment group); two 
known genes (PTP4A1, FBXO31) and two uncharacterised 
genes (ENSG00000256940, ENSG00000257742).
Principal component analysis of read count data revealed con-
siderable within-group variation in the one-month samples 
(Figure 1). The raw read count matrix for all 96 samples and 
11424 genes was entered into coexpression analysis using a 
Pearson correlation cut-off of 0.93. This generated three clusters 
of samples (data not shown). Nine samples were not 
included in any cluster and had no class. Treatment/outcome 
group samples at baseline and one month appeared to distrib-
ute evenly across all three clusters, with the exception of the 
placebo-Poor one-month samples, which were all found in 
cluster one (with the exception of one sample that had no class).
The raw read count matrix for all samples was inverted and 
analysed again for networks of co-expressed genes. Using 
a Pearson correlation cut-off of 0.88, 40 clusters of genes 
were identified. Genes in each of the ten largest clusters (con-
taining ≥9 genes) were entered into pathway analysis using 
the background of 11424 genes included in differential expres-
sion testing. The largest cluster, cluster 1, was highly enriched 
for pathways associated with wound healing (Extended data). 
With the exception of cluster 8, which was enriched for phago-
cytosis-related genes, all other clusters were enriched for cell 
Table 4. Pairwise contrasts of within-group differences (between baseline and one-







Placebo-Poor vs. Placebo-Good b 4 3 1
Doxycycline-Poor vs. Doxycycline-Good b 1 - 1
Placebo-Good vs. Doxycycline-Good 0 - -
Placebo-Poor vs. Doxycycline-Poor 0 - -
All placebo vs. Doxycycline 0 - -
All Good vs. Poor outcome 4 3 1
b Upregulated genes had higher expression in the Poor outcome group
Table 3. The ten most enriched pathways within each treatment/outcome group at one-month post-surgery relative to baseline. 
Pathways are ranked in order of significance. For all pathways shown, the enrichment P value was <2 x 10-10.
Placebo-Good Placebo-Poor Doxycycline-Good Doxycycline-Poor
Extracellular matrix 
organization
Extracellular matrix organization Extracellular matrix organization Extracellular matrix organization
Collagen formation Beta1 integrin cell surface 
interactions
Collagen formation Collagen formation
Beta1 integrin cell surface 
interactions
Collagen formation Beta1 integrin cell surface 
interactions
Collagen biosynthesis and 
modifying enzymes
Collagen chain trimerization Cell adhesion molecules (CAMs) - 
Homo sapiens (human)
Integrin Class A/1 (Rhodopsin-like 
receptors)
Collagen biosynthesis and 
modifying enzymes
Hematopoietic cell lineage - Homo 
sapiens (human)





- Homo sapiens (human)
Staphylococcus aureus infection 
- Homo sapiens (human)
ECM-receptor interaction - Homo 
sapiens (human)
Beta1 integrin cell surface 
interactions
Degradation of the 
extracellular matrix
Collagen chain trimerization Cell adhesion molecules (CAMs) 
- Homo sapiens (human)
Collagen chain trimerization
Integrin Complement and coagulation 
cascades - Homo sapiens (human)
ECM proteoglycans Interleukin-4 and 13 signalling
Focal Adhesion Collagen biosynthesis and 
modifying enzymes
Beta3 integrin cell surface 
interactions
Regulation of Complement 
cascade




Degradation of the extracellular 
matrix
ECM proteoglycans
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cycle and pathways of general cellular processes (Extended 
data). In order to determine whether these tightly co-expressed 
gene clusters were differentially expressed between treat-
ment/outcome groups, the read counts for all genes in each 
cluster were summed for each individual. The expression 
of each cluster-sum was then compared between groups at 
one month by linear regression, adjusting for cluster-sum 
expression at baseline (prior to surgery), age and sex. 
The summative expression of the 20 genes in cluster one, which 
was strongly enriched for pro-fibrotic pathways, was higher 
in those with a Poor outcome relative to those with a Good out-
come in the placebo group (P=0.017). The summative expres-
sion of cluster one genes was not different in the doxycycline 
group in those with Good or Poor outcomes relative to the 
placebo-Good group however. There was no evidence of 
differential expression of clusters 2–10 between treatment/ 
outcome groups.
Gene expression
The genes in cluster 1, which were enriched for pro-fibrotic 
pathways and were more highly expressed in individuals who 
developed a Poor outcome relative to Good outcome in the 
placebo arm, were tested by qPCR in a larger sample of 
individuals to validate their differential expression. A number 
of other genes hypothesised to be involved in the development 
of ECA or to be immunomodulated by doxycycline were also 
tested1,10,14–17,22,26,27. Of the 1000 participants in the clinical 
trial, a total of 145 had developed moderate or severe ECA at 
one month5. These 145 individuals and 145 age, sex and trial 
arm matched individuals who had not developed a Poor 
outcome by 1 month were selected for qPCR validation of gene 
expression, using samples from baseline, one month and six 
months (Table 5).
Of the 145 individuals with Poor outcomes (moderate or severe 
ECA) at one month, 48 had improved to ECA grade 0 at six 
months; 22 in the doxycycline and 26 in the placebo treatment 
arms. A binary ECA variable was therefore generated for qPCR 
analyses, defined as none/mild (ECA grade 0/1) and moderate/ 
severe (ECA grade 0/1) at each of the one and six-month 
time-points. There was no difference in baseline trichiasis 
grade (P=0.8), baseline papillary inflammation (P=0.39), 
baseline conjunctival scarring grade (P=0.71), or surgeon (P=0.72) 
between those with and without ECA.
Two genes were filtered out prior to analysis due to having >10% 
missing data (PAPPA and TRGV9), leaving 44 genes of inter-
est in the analysis. Twenty-six of these genes were strongly 
associated with ECA (at the FDR adjusted P value thresh-
old of 0.0036), all of which were upregulated, reflected by 
an odds ratio less than one (delta CT values were used in the 
analysis) (Table 6).
Of the 20 genes in cluster 1, 17 were tested by qPCR (three 
collagen alpha variants were excluded; COL1A2, COL5A2, 
COL6A3). Furthermore PAPPA, which was in cluster 1 and was 
tested by qPCR, was excluded during quality control. All 17 
Figure 1. Principal component analysis of read count data from baseline and one-month samples.
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genes from cluster 1 that were tested by qPCR were strongly 
associated with ECA (P<0.0036). Of the genes that were 
selected for qPCR testing based on prior literature (total 
= 29), 10 were associated with ECA. These included pro- 
inflammatory chemokines and cytokines CCL2, CCL3, CXCL5, 
IL1B and IL6, matrix metalloproteinases MMP1 and MMP9, 
CHUK, FUT4 and PTPRC.
In order to determine whether any of the associations between 
gene expression and ECA were modulated by doxycycline, 
regression models were run again using data from baseline and 
one month only (since treatment was only administered for 
28 days after surgery). There was no strong evidence that any 
models including the interaction fitted the data better than the 
models without the interaction term (Table 7), suggesting that 
doxycycline treatment did not modulate the association between 
conjunctival gene expression and ECA. There was weak evidence 
for interactions in CD68, IL10, IFNG and MMP12.
Discussion
Here we present evidence that a number of pro-fibrotic and 
pro-inflammatory genes were upregulated in the conjunctivae 
of patients who developed ECA following trichiasis surgery. 
Analysis of 3’RNA sequencing data revealed that all treat-
ment/outcome groups upregulated wound healing pathways 
at one-month post-surgery, however surprisingly, there were 
no differences in the expression of individual genes between 
groups. Visualisation of global gene expression by PCA revealed 
considerable variation amongst one-month samples relative to 
baseline samples. Clusters of highly coexpressed genes were 
identified in the raw data, the largest of which was enriched 
for pro-fibrotic pathways. The summed expression of this clus-
ter of coexpressed genes was upregulated in individuals with 
a Poor outcome relative to those with a Good outcome in the 
placebo group. However, this cluster was not upregulated in 
the doxycycline-treated Poor outcome group. The expression 
of the genes in this cluster and a number of other immune 
response genes hypothesised to be associated with ECA 
and reported to be immunomodulated by doxycycline were 
evaluated in a larger number of participants by qPCR at 
baseline, one and six months. The results showed that all 
genes tested within this pro-fibrotic cluster and a number of 
the other pro-inflammatory genes were strongly associated 
with ECA, adjusting for trial arm, age and sex. No strong 
Table 5. Clinical and demographic details of 290 participants used for qPCR 
validation.
Outcome Good outcome Poor outcome
Treatment arm Placebo Doxycycline Placebo Doxycycline
Total 72 73 72 73
Age (mean, range) 54.5 (26–80) 56.9 (34–82) 54.9 (24–80) 57.5 (30–80)
Sex (female/2) 57 53 57 53
C. trachomatis detected:
Baseline 3 0 0 1
1 month 1 0 0 0
6 months 2 0 0 1
Scarring at baseline:
C0 0 0 0 0
C1 2 2 4 7
C2 59 61 61 57
C3 11 10 7 9
ECA at one month:
none 51 55 0 0
Grade 1 21 18 0 0
Grade 2 0 0 64 60
Grade 3 0 0 8 13
ECA at six months:
none 64 68 26 22
Grade 1 6 3 23 25
Grade 2 2 2 21 20
Grade 3 0 0 2 4
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evidence was found to suggest that doxycycline treatment had an 
immunomodulatory effect on the association between gene 
expression and ECA.
The genes strongly associated with ECA included all tested 
members of cluster one (enriched for collagen biosynthe-
sis/formation, integrin interactions and extracellular matrix 
organisation pathways), pro-inflammatory cytokines and 
chemokines (CCL2, CCL3, CXCL5, IL1B and IL6), matrix 
metalloproteinases MMP1 and MMP9, CHUK (also known as 
IKK-α, an inhibitory regulator of NFκB transcription factor), 
FUT4 (also known as CD15, a cellular marker of granulo-
cytes), and PTPRC (also known as CD45 or common leukocyte 
antigen). All associated genes were upregulated in individuals 
with ECA.
The upregulation of pro-inflammatory mediators and cell mark-
ers (CCL2, CCL3, CXCL5, IL1B, IL6, CHUK, FUT4 and PTPRC) 
is indicative of higher levels of inflammation and leukocyte 
infiltration in the conjunctival tissue of patients who devel-
oped ECA following trichiasis surgery. Inflammation is a crucial 
stage of the wound healing process, necessary to attract leuko-
cytes to the wound site to remove debris and pathogens and to 
trigger the subsequent proliferative stage. Excessive inflam-
mation can lead to fibrotic pathology; however an increase in 
pro-inflammatory cytokines was associated with poor progno-
sis following glaucoma filtration surgery31. The factors underly-
ing the increased inflammation in these individuals is unclear; 
there was no difference in baseline clinical inflammation grade 
between those that did and did not develop ECA. Risk factors 
associated with ECA development include baseline trichiasis 
severity and older age32,33, however there was no difference 
in baseline age or trichiasis severity in those with and with-
out ECA in this study. Intersurgeon variability and distance 
between sutures were also associated with ECA development 
Table 7. Evidence for 
interaction between 
doxycycline treatment and 
gene expression in their 
effect on ECA. 
P values are shown for each 
gene of a likelihood ratio 
test, examining whether 
a mixed effects logistic 
regression model including 
an interaction term between 
treatment arm and gene 
expression explained the 
data better than a model 
without the interaction 
term. P values <0.001 are 
considered significant after 
adjustment for the 5% FDR.
















































Page 12 of 20
Wellcome Open Research 2019, 4:130 Last updated: 01 FEB 2021
following PLTR surgery33, however there was no difference 
between surgeon and ECA outcome in this trial.
A number of pro-fibrotic genes were upregulated in individu-
als with ECA, including VCAN, FN1, SPARC and FERMT2 
(proteins that constitute the ECM or regulate the interac-
tions between cells and the ECM), matrix metalloprotein-
ases MMP1 and MMP9 and pro-fibrotic growth factors CTGF, 
TGFB1 and TGFB1|1. MMPs are involved in multiple stages of 
wound healing and are crucial for matrix remodelling during 
the tissue regeneration process34. However, excessive produc-
tion of MMPs is often associated with pathology and over-
expression of MMPs 1, 2, 8, 12 and 13 correlated with levels 
of corneal fibrosis in patients requiring penetrating and deep 
anterior lamellar keratoplasty35. TGFβ is a key regulator of 
the wound healing process and regulates cellular differentia-
tion and proliferation, ECM production and wound contraction. 
TGFβ is also thought to orchestrate fibrotic outcomes follow-
ing glaucoma filtration surgery36 and it induces tissue contrac-
tion and fibronectin production by conjunctival fibroblasts37. 
Furthermore, increased expression of fibronectin and integrin 
α5β1 are thought to mediate TGFβ-induced myofibroblast 
differentiation38, which have high contractile activity. The 
upregulation of these pro-fibrotic and matrix factors in patients 
with ECA likely reflects excessive remodelling and contraction of 
the conjunctival tissue.
Type I, III, V, VI and VII collagen transcripts were strongly 
upregulated in individuals with ECA and were all found in 
co-expression cluster one. Collagens are fibrous proteins that 
make up the connective tissue and collagen type I is the major 
constituent of the ECM39. Early on during the wound healing 
process myofibroblasts are thought to produce collagen type 
III, which is later replaced by collagen type I40. Collagen types 
III, V and VI have been found to be increased in pathological 
scarring conditions41–44. In tissue from normal conjunctiva 
examined by immunohistochemistry, collagen types I and III 
were limited to the substantia propria and collagen type V 
was absent, whereas in inflammatory and scarring trachoma 
increased collagen type IV was detected in the thickened base-
ment membrane and new collagen type V was deposited in the 
upper substantia propria45,46. A number of collagen transcripts 
and proteins, in particular collagen types I, VIII and XI, 
were associated with pathological scarring in the conjunctiva 
following glaucoma filtration surgery in mice and humans13.
Contrary to our hypothesis, we found no strong evidence for 
modulation of the association between gene expression and 
ECA development by doxycycline treatment. In support of 
this finding there was no evidence that doxycycline treatment 
reduced the risk of developing post-operative trichiasis or ECA 
in the overall trial5. These findings are somewhat surprising 
given the evidence supporting the clinical use of oral doxycycline 
to reduce inflammation and fibrosis in various diseases includ-
ing rosacea, idiopathic pulmonary fibrosis, chronic blephari-
tis, corneal erosion and corneal melting post-Pseudomonas 
infection19–21,47–49. Furthermore, doxycycline treatment 
in vitro reduced MMP1, 9 and 12 expression by primary 
fibroblasts from trichiasis patients and reduced collagen matrix 
contraction22. Treatment was taken every day for 28 days 
prior to collection of the one-month sample therefore levels 
of active drug in the body should have remained high, and the 
positive impact of oral doxycycline on corneal and other skin 
diseases suggests that it successfully penetrates the epithelium. 
Oral doxycycline administered for three weeks was found to 
have no benefit in patients with persistent symptoms follow-
ing treatment for neuroborreliosis (a neurological manifestation 
of tick-borne Lyme disease); there was no difference in 
symptoms relative to a placebo group and no change in 
systemic cytokine responses50. It is possible that in the context 
of trichiasis surgery, doxycycline either has no immunomodula-
tory effect or it does not immunomodulate the factors involved 
in recurrent trichiasis and ECA.
Although a large number of genes were upregulated in all treat-
ment/outcome groups at one-month post-surgery by RNA 
sequencing, no differences were detected between groups. 
This was probably due to the small sample size and high 
degree of variation in the one-month samples, evident by PCA. 
Reducing this variation through summed expression of coex-
pressed gene clusters revealed differences in wound healing 
pathways that were validated by qPCR. A strength of this study 
was the original trial design, including standardisation of 
surgery, patient treatment adherence and follow up. This 
study was designed and targets were chosen for follow-up 
to investigate the immuno-fibrogenic factors associated with 
the development of ECA, therefore it was not appropriate to 
reanalyse the results in relation to trachomatous trichi-
asis recurrence (reported elsewhere10) or ECA regression; in 
addition, these analyses would have had small group sizes.
This study has revealed that the development of post- 
operative ECA is strongly associated with the upregulation of 
pro-fibrotic genes, including growth factors (and the canonical 
fibrogenic growth factor TGFB1), matrix proteins and collagens. 
A number of MMPs and pro-inflammatory cytokines were also 
upregulated. Contrary to our hypothesis, there was no 
strong evidence to suggest that doxycycline modulated the 
relationship between gene expression and ECA. Although it 
is reassuring that ECA regressed in roughly a third of patients 
by 6 months, the short-term aesthetic appearance may still 
dissuade others from undergoing trichiasis surgery and anti- 
fibrotic treatments to prevent ECA development remain desirable. 
Data availability
Underlying data
Raw and processed RNAseq data for ‘The conjunctival tran-
scriptome in Ethiopians after trichiasis surgery: associations 
with the development of eyelid contour abnormalities and 
the effect of oral doxycycline treatment’, Accession number 
GSE135455: https://identifiers.org/geo:GSE135455
Figshare: The conjunctival transcriptome in Ethiopians after 
trichiasis surgery: associations with the development of eye-
lid contour abnormalities and the effect of oral doxycycline 
treatment, https://doi.org/10.6084/m9.figshare.9696143.v151
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This project contains the following underlying data:
- Raw and processed qPCR data
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Extended data
Figshare: EXTENDED DATA [The conjunctival transcrip-
tome in Ethiopians after trichiasis surgery: associations with the 
development of eyelid contour abnormalities and the effect of 
oral doxycycline treatment], https://doi.org/10.6084/
m9.figshare.9696263.v152
This project contains the following extended data:
-    Clusters of co-expressed genes in the raw read count 
matrix for all samples. Using a Pearson correlation 
cut-off of 0.88, 40 clusters were identified. Panel A 
shows the names of genes in each cluster. Panel B shows 
the ten most enriched pathways for the genes in each 
cluster. Panel C shows results of differential expression 
testing of the cluster-sum (summed read counts of all 
genes in the cluster for each individual), adjusting for 
baseline cluster-sum expression, age and sex. Each group 
was compared to the reference group of Placebo-Good 
outcome.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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This study sought to investigate the transcriptional changes associated with the early 
development of eyelid contour abnormalities (ECA) following trichiasis surgery. It also aimed to 
evaluate the effects of doxycycline on such transcription patterns. 
 
The research question is important. Despite being a significant cause of ocular morbidity, the 
underlying mechanisms of ECA development following trichiasis surgery is unclear. This translates 
to a lack of effective therapies for the prevention or treatment of ECA.  ECA is also an important 
reason why patients with trachoma refuse sight-saving trichiasis surgeries. Thus, understanding 
the transcriptional changes is an important step forward in figuring out the pathophysiology of 
ECA and the development of potentially more effective therapies. Furthermore, doxycycline is a 
widely used drug for inflammatory disorders of the ocular surface. Establishing the anti-
inflammatory and anti-fibrotic effects of oral doxycycline in trachomatous lid pathologies is thus 
clinically relevant. 
 
The study was designed within a randomised, double-masked, placebo-controlled trial. This is 
appropriate to address the study hypothesis. The work performed by the authors has been 
presented well with methodologies and analyses clearly described. 
 
Some minor points to consider:
Abstract: ‘12 in each treatment/ECA outcome group’ requires more description. From the 
abstract, it is unclear to the reader, what these groups are. It is only available in the 
methods section of the main manuscript. 
 
1. 
Methods: The nurse-surgeons have been described as ‘experienced’. Perhaps a 
quantification of the number of years of experience (e.g. median or range) of the nurses 
2. 
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should be included. Also, how many nurse-surgeons were involved in this study? 
 
Methods: As this is within an RCT, the method of randomisation should be described. 
 
3. 




Methods: Of the 98 samples that failed QC, which groups were the samples from? Was the 
number of failed samples relatively equal in the moderate/severe ECA group compared to 
samples taken from individuals without/mild ECA? 
 
5. 
Methods: Details of the power calculation for both analyses should be included. Were the 
sample sizes adequate to detect differences between the groups for the RNA seq 
experiments? Also, the power of the study is relevant as the study reported results showing 
no evidence of doxycycline treatment affecting gene expression and ECA development. 
 
6. 
Results: The first paragraph of the results have been described in the Methods section and 
can probably be left out. 
 
7. 
Results: For table 1, were there significant differences in the baseline characteristics 
between the groups? 
 
8. 
Results: For table 2, it appears that more genes were up-regulated in poor outcome groups 
compared to control groups. Also, there were a higher number of differentially expressed 




Results: For table 5, were there significant differences in the baseline clinical and 
demographic characteristics between the groups? 
 
10. 
Discussion: The authors could perhaps include a short paragraph on the relevance of their 
transcriptome findings on understanding the pathophysiology of ECA development and 
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This manuscript reports data from a novel study investigating the association between gene 
expression patterns and eyelid contour abnormality development following trichiasis surgery. This 
is an important study, as little is known about the pathophysiology of ECAs in this population.  
 
The manuscript is well written and describes in detail the analyses used. 
  
Prior research has demonstrated that the immediate post-operative appearance has a significant 
impact on both return of trichiasis and the development of eyelid contour abnormalities. At 
present, the manuscript does not address this issue. The following recommendations should be 
considered for addressing this gap: 
In the introduction, paragraph 3, it would be useful to discuss the existing literature on the 
association between surgical appearance and subsequent ECAs (where the authors discuss 
that the pathophysiology is unknown). 
 
○
In a masked fashion, review the post-operative photos (either immediate or 1 day) to assess 
the eyelid contour for the 48 individuals included in the primary analyses and report 
whether there are differences between groups.  
 
○
Evaluate the impact of the post-operative contour on the genetic results. It is likely that both 
the contour and the underlying genetic upregulation both impact the development of ECA, 
○
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and possibly the regression of ECAs seen in the early post-operative period, but not at later 
visits. 
Methods: 
Exam section, last paragraph: Please clarify that it is the conjunctival scarring that was graded with 
the FPC system. 
  
Last paragraph before data analysis: Were the samples that failed randomly distributed or were 
they more commonly from one or more groups - either one of the 4 groups, or did they vary by 
age and/or sex. 
  
There is a bit of a mix of methods in the results and results in the methods section. Recognizing 
that sometimes it is important to describe results of intermediate steps in the methods when they 
influence the next set of methods, please review and consider not repeating specific aspects. For 
example, the first paragraph of the results is nearly a copy/paste from the methods. 
  
Discussion: 
Bottom of page 12: Please include discussion regarding prior research that has shown a strong 
association between immediate post-op appearance and early outcomes. [Merbs, PLOS NTD 2012 
reports that 85% of the time ECAs were predicted based on immediate post-op appearance] 
 
Minor suggestions:  
In the introduction the word “recurrence” is used instead of post-operative trichiasis. In keeping 
with WHO recommendation, it would be good to use the latter instead. 
  
The introduction reports 12-22% “recurrence” within 12 months after surgery and then cites the 
study used for this analysis and one other by this group. There is a much broader range of PTT 
rates, and studies have been reported by other groups. This statement should be modified to 
reflect the range of rates reported in the literature. 
  
Please check references in the 3rd paragraph of the introduction. At present, the second sentence 
references the grading scheme for ECAs, but is discussing the corneal damage and vision loss 
associated with ECAs.  
 
Same paragraph, “patient’s” should be “patients’” 
  
Second to last paragraph of introduction: please add numbers or %s regarding ECAs, as was done 
with the TT numbers.
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